EAU 2022: Sustained Castration to 20 ng/dl for Relugolix vs. Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study

EAU 2022 Bertrand Tombal HERO study, relugolix versus leuprolide in men with advanced prostate cancer relugolix demonstrated more rapid and sustained profound testosterone suppression compared with leuprolide in the phase 3 HERO study

Read the full article here

Related Articles